Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Table 4 Adverse events

Adverse events	Studies, n	Heterogeneity test, I2(%)	Heterogeneity test, P value	Model	RR	95%CI	P value
All adverse events	3	0	0.53	Random	0.97	0.79-1.20	0.80
Abdominal pain	4	0	0.68	Random	0.95	0.65-1.41	0.81
Fever	3	0	0.66	Random	0.95	0.72-1.25	0.69
Fatigue	4	0	0.68	Random	1.28	0.79-2.05	0.32
Nausea and vomiting	5	0	0.70	Random	1.25	0.85-1.83	0.25
Decreased appetite	5	0	0.76	Random	1.18	0.81-1.71	0.40
Liver dysfunction	4	0	0.46	Random	1.04	0.62-1.75	0.87
Hypertension	5	0	0.44	Random	2.53	1.19-5.39	0.02
Hand-foot skin reaction	5	75	0.003	Random	0.74	0.18-3.04	0.68
Diarrhea	6	39	0.16	Random	1.38	0.55-3.44	0.49
Thrombocytopenia	3	0	0.71	Random	1.18	0.71-1.98	0.52
Rash	6	65	0.04	Random	0.88	0.19-4.16	0.88

RR: Relative risk; CI: Confidence interval.